JMP Securities Reiterates Market Outperform Rating on Exelixis (EXEL)

JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating and $41.00 price target on Exelixis (NASDAQ: EXEL)

The analyst commented, “Exelixis shares have been weak ahead of this weekend's zanza update. We believe data is supportive of the CRC opportunity (details below). Based on conversations with management, we have a positive outlook on the probability of success of the STELLAR-303 study (data in 2H25) in non-liver metastases (NLM) mCRC patients, an ~$1B opportunity at peak based on our estimates. We maintain our Market Outperform rating and $41 DCF-derived price target.”

For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.

Shares of Exelixis closed at $32.38 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Boeing lands two U.S. defense contracts worth over $711M
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027